Slideshow
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
-
provenge-sipuleucel-t-drug-showcase-prostate-cance
This slideshow reviews drug information for PROVENGE® (sipuleucel-T), indicated for metastatic castration-resistant prostate cancer (mCRPC).
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 6: Use in Specific Populations
Slide 8: Clinical Pharmacology
Slide 12: Warnings and Precautions
Slide 15: Clinical Safety and Efficacy
Slide 21: Drug Storage and SupplySlide 23: References
